Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

iOMEDICO AG49 enrolled

Overview

The objective of this non-interventional study (NIS) is to evaluate tucatinib (TUKYSA®) combined with trastuzumab and capecitabine in adult patients with locally advanced or metastatic HER2-positive breast cancer who have been previously treated with at least two anti-HER2 treatment regimens in a real-world setting,

TRACE will collect real-world data on the treatment of tucatinib/trastuzumab/capecitabine in a broad patient population including older patients and patients with more comorbidities as compared to the pivotal trial HER2CLIMB. In contrast to HER2CLIMB, TRACE will also include patients receiving tucatinib/trastuzumab/capecitabine during 1st and 2nd palliative therapy line who were primarily diagnosed with early breast cancer and therefore already have received two prior anti-HER2 based treatment regimens before enrollment. Until today, no reliable data is available for these patient population. TRACE will primarily focus on HRQoL using the validated EORTC QLQ C30 + QLQ-BR23 + EQ-5D-5L questionnaires. Further aims are to evaluate effectiveness and safety in distinct subgroups focusing on effectiveness of tucatinib/trastuzumab/capecitabine in patients who have experienced prior therapies with trastuzumab and neratinib or capecitabine and HER2-targeted TKIs in the neoadjuvant, adjuvant or palliative setting, respectively. Study sites may retrospectively include patients within 9 weeks (corresponds to 3 cycles) after start of study treatment up to 6 months after activation of respective site. Retrospectively included patients may have already completed study treatment or may have already deceased at the time of inclusion.

Study Type

OBSERVATIONAL

Enrollment

Conditions

HER2-positive Breast Cancer

Interventions

TUKYSA®DRUG

tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged 18 years or older. * Histologically confirmed HER2+ breast cancer with HER2 positivity defined as a 3+ score by immunohistochemistry (IHC) or a positive result by in situ hybridization (ISH), optionally combined with a IHC2+ score. * Diagnosis of locally advanced or metastatic HER2+ breast cancer, including patients with brain metastases. * Prior treatment with at least two prior anti-HER2-based regimens. * Decision for treatment with tucatinib in combination with trastuzumab and capecitabine according to current SmPC of tucatinib either in 1st/2nd palliative treatment line (Cohort 1) or 3rd/4th palliative treatment line (Cohort 2). * Progression after or intolerance of last systemic anti-HER2-based therapy. * Indication for treatment with tucatinib as assessed by the treating physician. * Signed written informed consent (only if patient is alive at time of inclusion, not applicable for retrospective inclusion of deceased patients). * Knowledge of German language. * Other criteria according to current SmPC of tucatinib Exclusion Criteria: * Contraindications according to SmPC of tucatinib * Participation in an interventional clinical trial within 30 days prior to enrolment or simultaneous participation in an interventional clinical trial. * Treatment with tucatinib/trastuzumab/capecitabine (=study treatment) in 5th or higher palliative therapy line. * Onset of tucatinib treatment later than 22 days after start of therapy line (in case tucatinib administration is started later than trastuzumab and/or capecitabine for any reason)

Locations (2)

Medizinische Universität Wien, Innere Medizin I, Hämatologie und Onkologie

Vienna, Austria

Universitätsklinikum Essen, Innere Klinik (Tumorforschung)

Essen, North Rhine-Westphalia, Germany

Outcomes

Primary Outcomes

Time to deterioration of EORTC global health scale by at least 10 points

Only for prospectively enrolled patients: Time to deterioration of EORTC global health scale is defined as the time interval between fill-in date of baseline questionnaire and the first decrease in global health scale score ≥ 10-point (compared to baseline). If there was no such decrease, death will serve as event for this analysis, if occurring within 4 months after last filled-in questionnaire.

Time frame: Baseline, up to 24 months

Changes in the global health scale

Only for prospectively enrolled patients: Changes in global health is provided by descriptive statistics of the EQ-5D-5L index value, the EQ-5D-5L visual analogue scale, the EORTC QLQ-C30 global health scale and all functional and symptom scores of the EORTC questionnaires.

Time frame: Baseline, up to 24 months

Secondary Outcomes

Time to next systemic treatment (TTNT)

TTNT (time to next systemic treatment) is defined as time from first administration of any study treatment (i.e., tucatinib/trastuzumab/capecitabine treatment) to start of a subsequent systemic antineoplastic therapy or death, whichever comes first.

Time frame: Baseline, up to 5 years

Time to local intracranial treatment (TLT)

TLT (time to local intracranial treatment) is defined as time from first administration of any study treatment to start of a local intracranial therapy, end of a treatment interruption due to isolated intracranial progression, change of treatment strategy or death, whichever comes first. It will be analyzed for patients with isolated intracranial progression after start of study treatment.

Time frame: Baseline, up to 5 years

Overall response rate (ORR)

ORR is defined as proportion of patients with any response (partial or complete remission) overall.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.